https://www.selleckchem.com/pr....oducts/emricasan-idn
A total of 13 eligible studies with 1980 patients were included in this meta-analysis. Low NDRG2 expression was significantly associated with poor OS (HR = 1.96, 95% CI 1.60-2.40, P .001) and DFS (HR = 2.70, 95% CI 1.42-5.13, P = .002) in solid tumor. Furthermore, low NDRG2 expression was related to some phenotypes of tumor aggressiveness, such as clinical stage (OR = 3.21, 95% CI 1.96-5.26, P .001), lymph node metastasis (OR = 2.14, 95% CI 1.49-3.07, P .001), and degree of differentiation (OR = 0.6
Like
Comment
Share
